{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma&page=11", "query": { "condition": "Lymphoma", "page": 11 }, "page_size": 10 }, "pagination": { "page": 11, "page_size": 10, "total_count": 5753, "total_pages": 576, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma&page=12&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma&page=10&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-24T10:08:53.755Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00655668", "title": "A Phase II Study of Single-Agent Lenalidomide in Subjects With Relapsed Or Refractory T-Cell Non-Hodgkin's Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "T-cell Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2008-03-01", "completion_date": "2010-04-01", "has_results": true, "last_update_posted_date": "2019-11-25", "last_synced_at": "2026-10-24T10:08:53.755Z", "location_count": 4, "location_summary": "Beverly Hills, California • Wichita, Kansas • Hackensack, New Jersey + 1 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Wichita", "state": "Kansas" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00655668" }, { "nct_id": "NCT00421213", "title": "Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hematologic Neoplasms", "Bone Marrow Neoplasms", "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "Darinaparsin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alaunos Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2006-12-29", "completion_date": "2009-06-30", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-24T10:08:53.755Z", "location_count": 6, "location_summary": "Miami, Florida • Chicago, Illinois • Bethesda, Maryland + 3 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Fargo", "state": "North Dakota" }, { "city": "Sioux Falls", "state": "South Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00421213" }, { "nct_id": "NCT01055496", "title": "Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma, B-Cell" ], "interventions": [ { "name": "inotuzumab ozogamicin+rituximab +cyclophosphamide+vincristine+prednisone", "type": "DRUG" }, { "name": "inotuzumab ozogamicin+rituximab+gemcitabine+cisplatinum+dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 103, "start_date": "2010-03", "completion_date": "2014-03", "has_results": true, "last_update_posted_date": "2019-08-02", "last_synced_at": "2026-10-24T10:08:53.755Z", "location_count": 10, "location_summary": "Gainesville, Florida • Philadelphia, Pennsylvania • Houston, Texas + 5 more", "locations": [ { "city": "Gainesville", "state": "Florida" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01055496" }, { "nct_id": "NCT03719560", "title": "Early Systemic Central Nervous System Prophylaxis in Diffuse Large B-cell Lymphoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse Large B Cell Lymphoma" ], "interventions": [ { "name": "Methotrexate", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2019-07-01", "completion_date": "2025-12-31", "has_results": false, "last_update_posted_date": "2020-04-13", "last_synced_at": "2026-10-24T10:08:53.755Z", "location_count": 1, "location_summary": "Providence, Rhode Island", "locations": [ { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT03719560" }, { "nct_id": "NCT00061880", "title": "BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "forodesine hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioCryst Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2003-02", "completion_date": "2008-01", "has_results": false, "last_update_posted_date": "2013-05-30", "last_synced_at": "2026-10-24T10:08:53.755Z", "location_count": 3, "location_summary": "Birmingham, Alabama • Durham, North Carolina • Houston, Texas", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00061880" }, { "nct_id": "NCT00809276", "title": "Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma", "Multiple Myeloma", "Leukemia", "Myelodysplastic Syndrome" ], "interventions": [ { "name": "Busulfan, Fludarabine, Cytoxan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "65 Years", "sex": "ALL", "summary": "Up to 65 Years" }, "enrollment_count": 92, "start_date": "2009-05", "completion_date": "2011-12", "has_results": true, "last_update_posted_date": "2015-02-16", "last_synced_at": "2026-10-24T10:08:53.755Z", "location_count": 3, "location_summary": "Baltimore, Maryland • Houston, Texas • Seattle, Washington", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Houston", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00809276" }, { "nct_id": "NCT00125840", "title": "Clofarabine in Adult Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors", "Leukemia, Lymphocytic, Acute, Pediatric", "Leukemia, Lymphocytic, Acute, Adult", "Leukemia, Myelocytic, Acute, Pediatric", "Leukemia, Myelocytic, Acute, Adult", "Myelodysplastic Syndromes, Adult" ], "interventions": [ { "name": "clofarabine (IV formulation)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genzyme, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2002-08", "completion_date": "2007-08", "has_results": false, "last_update_posted_date": "2014-02-05", "last_synced_at": "2026-10-24T10:08:53.755Z", "location_count": 2, "location_summary": "Dallas, Texas • Tyler, Texas", "locations": [ { "city": "Dallas", "state": "Texas" }, { "city": "Tyler", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00125840" }, { "nct_id": "NCT01475058", "title": "CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia", "Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Mantle Cell Lymphoma", "Refractory Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "allogeneic cytomegalovirus-specific cytotoxic T lymphocytes", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 1, "start_date": "2012-04", "completion_date": "2014-07", "has_results": false, "last_update_posted_date": "2017-02-15", "last_synced_at": "2026-10-24T10:08:53.755Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01475058" }, { "nct_id": "NCT00082017", "title": "UCN-01 (7-Hydroxystaurosporine) to Treat Relapsed T-Cell Lymphomas", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma, Large-Cell, Ki-1", "Lymphoma, T-Cell" ], "interventions": [ { "name": "UCN-01 (7-hydroxystaurosporine)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 20, "start_date": "2004-04-05", "completion_date": "2011-09-27", "has_results": true, "last_update_posted_date": "2017-05-15", "last_synced_at": "2026-10-24T10:08:53.755Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00082017" }, { "nct_id": "NCT07082868", "title": "A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Primary Central Nervous System Lymphoma (PCNSL)", "Primary Central Nervous System Lymphoma", "Relapsed Primary Central Nervous System Lymphoma", "Refractory Primary Central Nervous System Lymphoma", "Central Nervous System Lymphoma", "Secondary Central Nervous System Lymphoma", "Secondary Central Nervous System Lymphoma (SCNSL)" ], "interventions": [ { "name": "ibrutinib", "type": "DRUG" }, { "name": "Epcoritamab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2025-08-13", "completion_date": "2028-08", "has_results": false, "last_update_posted_date": "2026-07-14", "last_synced_at": "2026-10-24T10:08:53.755Z", "location_count": 8, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07082868" } ] }